Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

NCT06582875 on ClinicalTrials.gov · last registry update 2025-05-06

Recruiting now, toward 126 participants. Due to report 30 June 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Change in height-Adjusted Total kidney volume. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Colorado, Denver
Sponsor type: Other
Enrollment: 126
Started: 2025-03-06
Primary completion: 2029-06-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in height-Adjusted Total kidney volume

Conditions studied

Autosomal Dominant Polycystic Kidney · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.